A randomized trial of ascorbic acid in polyposis coli - PubMed (original) (raw)
Clinical Trial
A randomized trial of ascorbic acid in polyposis coli
H J Bussey et al. Cancer. 1982.
Abstract
The possibility of pharmacological control of large bowel adenomas has been suggested by effectiveness of antioxidants in experimental tumor models and by the results of a limited clinical study using ascorbic acid. Over a two year period we tested this hypothesis in a randomized, double-blind study of 49 patients with polyposis coli. Of 36 patients who were evaluable at completion, 19 had received ascorbic acid, 3 g/day, and 17 had received a placebo. We found a reduction in polyp area in the ascorbic acid-treated group at nine months of follow-up (P less than 0.03) and trends toward reduction in both number and area of rectal polyps during the middle of the trial. A labeling study of rectal epithelium with tritiated thymidine also hinted at a treatment effect. Our data suggest that ascorbic acid temporarily influenced polyp growth or turnover. Although these results have no current therapeutic value, our findings support continued studies of chemoprevention in this and other high risk settings.
Similar articles
- Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis.
DeCosse JJ, Miller HH, Lesser ML. DeCosse JJ, et al. J Natl Cancer Inst. 1989 Sep 6;81(17):1290-7. doi: 10.1093/jnci/81.17.1290. J Natl Cancer Inst. 1989. PMID: 2549261 Clinical Trial. - Effect of ascorbic acid on rectal polyps of patients with familial polyposis.
DeCosse JJ, Adams MB, Kuzma JF, LoGerfo P, Condon RE. DeCosse JJ, et al. Surgery. 1975 Nov;78(5):608-12. Surgery. 1975. PMID: 1188603 - Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants.
Hofstad B, Almendingen K, Vatn M, Andersen SN, Owen RW, Larsen S, Osnes M. Hofstad B, et al. Digestion. 1998;59(2):148-56. doi: 10.1159/000007480. Digestion. 1998. PMID: 9586828 Clinical Trial. - Ascorbic acid does not cure cancer.
[No authors listed] [No authors listed] Nutr Rev. 1985 May;43(5):146-7. doi: 10.1111/j.1753-4887.1985.tb06894.x. Nutr Rev. 1985. PMID: 3897919 Review. No abstract available. - Large bowel adenomas: markers of risk and endpoints.
Baron JA. Baron JA. J Cell Biochem Suppl. 1996;25:142-8. J Cell Biochem Suppl. 1996. PMID: 9027611 Review.
Cited by
- Endoscopic scoring indices for assessing disease severity in familial adenomatous polyposis: Systematic review.
Silverman AL, Bouchiba H, Aelvoet A, MacDonald J, Dekker E, Zayadi A, Le J, Feagan B, Jairath V, Ma C, Samadder J. Silverman AL, et al. Endosc Int Open. 2024 Jun 18;12(6):E799-E809. doi: 10.1055/a-2330-8037. eCollection 2024 Jun. Endosc Int Open. 2024. PMID: 38904059 Free PMC article. Review. - Chemoprevention in hereditary digestive neoplasia: A comprehensive review.
Chevalier E, Benamouzig R. Chevalier E, et al. Therap Adv Gastroenterol. 2023 Dec 1;16:17562848231215585. doi: 10.1177/17562848231215585. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 38050626 Free PMC article. Review. - Updated Perspectives on the Diagnosis and Management of Familial Adenomatous Polyposis.
Kyriakidis F, Kogias D, Venou TM, Karlafti E, Paramythiotis D. Kyriakidis F, et al. Appl Clin Genet. 2023 Aug 14;16:139-153. doi: 10.2147/TACG.S372241. eCollection 2023. Appl Clin Genet. 2023. PMID: 37600856 Free PMC article. Review. - Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome.
Stone JK, Mehta NA, Singh H, El-Matary W, Bernstein CN. Stone JK, et al. Fam Cancer. 2023 Oct;22(4):413-422. doi: 10.1007/s10689-023-00334-3. Epub 2023 Apr 29. Fam Cancer. 2023. PMID: 37119510 Review. - Hereditary Colorectal Cancer Syndromes: Molecular Genetics and Precision Medicine.
Chen L, Ye L, Hu B. Chen L, et al. Biomedicines. 2022 Dec 10;10(12):3207. doi: 10.3390/biomedicines10123207. Biomedicines. 2022. PMID: 36551963 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical